Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study

References

• Lopez-CamposJLTanWSorianoJBGlobal burden of COPDRespirology2016211142326494423
   PubMed Web of Science ®Google Scholar
• World Health Organization [webpage on the Internet]Global Burden of Chronic Respiratory Disease2016 Available from: http://www.who.int/respiratory/copd/burden/en/Accessed May 3, 2016
   Google Scholar
• OhYMBhomeABBoonsawatWCharacteristics of stable chronic obstructive pulmonary disease patients in the pulmonology clinics of seven Asian citiesInt J Chron Obstruct Pulmon Dis20138313923378753
   PubMed Web of Science ®Google Scholar
• LimSLamDCMuttalifARImpact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based surveyAsia Pac Fam Med2015141425937817
   PubMedGoogle Scholar
• TanWCSealePIpMTrends in COPD mortality and hospitalizations in countries and regions of Asia-PacificRespirology2009141909719144054
   PubMed Web of Science ®Google Scholar
• ZhongNWangCYaoWPrevalence of chronic obstructive pulmonary disease in China: a large, population-based surveyAm J Respir Crit Care Med2007176875376017575095
   PubMed Web of Science ®Google Scholar
• CaramoriGAdcockIMPapiAClinical definition of COPD exacerbations and classification of their severitySouth Med J2009102327728219204646
   PubMed Web of Science ®Google Scholar
• AnzuetoAImpact of exacerbations on COPDEur Respir Rev20101911611311820956179
   PubMedGoogle Scholar
• WedzichaJASeemungalTACOPD exacerbations: defining their cause and preventionLancet2007370958978679617765528
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD) [homepage on the Internet]The Global Strategy for the Diagnosis, Management and Prevention of COPD2016 Available from: http://www.goldcopd.orgAccessed 3 May 2016
   Google Scholar
• National Institute for Health and Care Excellence (NICE)Chronic Obstructive Pulmonary Disease. Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. NICE Clinical Guideline 101 (Partial Update)LondonNational Institute for Health and Care Excellence (NICE)2010
   Google Scholar
• CrimCCalverleyPMAndersonJAPneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study resultsEur Respir J200934364164719443528
   PubMed Web of Science ®Google Scholar
• SuissaSPatenaudeVLapiFErnstPInhaled corticosteroids in COPD and the risk of serious pneumoniaThorax201368111029103624130228
   PubMed Web of Science ®Google Scholar
• MateraMGRoglianiPCazzolaMQVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary diseaseExpert Opin Pharmacother20151671079109025843089
   PubMed Web of Science ®Google Scholar
• ZhongNWangCZhouXLANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPDInt J Chron Obstruct Pulmon Dis2015101015102626082625
   PubMed Web of Science ®Google Scholar
• AsaiKMinakataYHirataKQVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: the ARISE studyEur Repir J2013423392
   Web of Science ®Google Scholar
• HashimotoSIkeuchiHMurataSKitawakiTIkedaKBanerjiDEfficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE studyInt J Chron Obstruct Pulmon Dis2016112543255127785010
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med1998157141814229603117
   PubMed Web of Science ®Google Scholar
• AnthonisenNRManfredaJWarrenCPHershfieldESHardingGKNelsonNAAntibiotic therapy in exacerbations of chronic obstructive pulmonary diseaseAnn Intern Med19871061962043492164
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• BlasiFCesanaGContiSThe clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patientsPLoS One201496e10122824971791
   PubMed Web of Science ®Google Scholar
• TanWCNgTPWhere east meets westChest200813351752718252918
   PubMed Web of Science ®Google Scholar
• YasudaSUZhangLHuangSMThe role of ethnicity in variability in response to drugs: focus on clinical pharmacology studiesClin Pharmacol Ther200884341742318615002
   PubMed Web of Science ®Google Scholar
• MartinABadrickEMathurRHullSEffect of ethnicity on the prevalence, severity, and management of COPD in general practiceBr J Gen Pract201262595e76e8122520773
   PubMed Web of Science ®Google Scholar
• FukuchiYFernandezLKuoHPEfficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trialRespirology201116582583521539680
   PubMed Web of Science ®Google Scholar
• SuzukiMMakitaHItoYMHokkaido COPD Cohort Study InvestigatorsClinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort studyEur Respir J20144351289129724232696
   PubMed Web of Science ®Google Scholar
• SeemungalTAHurstJRWedzichaJAExacerbation rate, health status and mortality in COPD – a review of potential interventionsInt J Chron Obstruct Pulmon Dis2009420322319554195
   PubMedGoogle Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• ZhengJZhongNNewlandsAChurchAGohAHEfficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled studyInt J Chron Obstruct Pulmon Dis2015101753176726366068
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• WedzichaJADahlRBuhlRPooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patientsRespir Med2014108101498150725135743
   PubMed Web of Science ®Google Scholar
• DahlRChapmanKRRudolfMSafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRespir Med2013107101558156723867808
   PubMed Web of Science ®Google Scholar
• DiSantostefanoRLSampsonTLeHVHindsDDavisKJBakerlyNDRisk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort studyPLoS One201495e9714924878543
   PubMed Web of Science ®Google Scholar
• ErnstPSaadNSuissaSInhaled corticosteroids in COPD: the clinical evidenceEur Respir J201545252553725537556
   PubMed Web of Science ®Google Scholar
• HizawaNLAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypesInt J Chron Obstruct Pulmon Dis2015101093110226089659
   PubMed Web of Science ®Google Scholar
• HoritaNKanekoTRole of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in JapanInt J Chron Obstruct Pulmon Dis20151081382225960646
   PubMed Web of Science ®Google Scholar
• SinghDNew combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectivesBr J Clin Pharmacol201579569570825377687
   PubMed Web of Science ®Google Scholar